@Article{or.2025.064119,
AUTHOR = {Xi Qin, Yulan Liu, Lin Zhu, Yunyan Mo, Jing Zhang, Zhuchun Jiang, Dongning Huang, Xinrong Hu, Jingzhang Li, Quanfang Chen, Feng Xue},
TITLE = {First-Line Aumolertinib in <i>EGFR</i>-Mutant Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Retrospective Study with a Four-Year Follow-Up},
JOURNAL = {Oncology Research},
VOLUME = {33},
YEAR = {2025},
NUMBER = {9},
PAGES = {2451--2462},
URL = {http://www.techscience.com/or/v33n9/63627},
ISSN = {1555-3906},
ABSTRACT = { <b>Background:</b> The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases. <b>Methods:</b> The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint. Adverse events (AEs) were assessed using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). <b>Results:</b> Approximately 47 patients with <i>EGFR</i>-Mutant aNSCLC were recruited, including 1 squamous cell carcinoma (SCC) patient, 1 <i>EGFR</i> G719C mutated patient, 1 <i>EGFR</i> S768 patient mutated, and 1 <i>EGFR</i> KDD mutated patient. The average follow-up duration was 48.1 months concluding in August 2024. The median PFS (mPFS) was 22.2 months (95% CI 17.6 to 26.7), while the median OS (mOS) was 39.7 months (95% CI 32.6 to 46.9). Patients with deletion of exon19 in <i>EGFR</i> (19del) showeda mPFS of 28.4 months, markedlylonger than those with the L858R point mutation (L858R), who had a mPFS of 15.2 months (<i>p</i> = 0.036). Overall, 22 patients (46.8%) had central nervous system (CNS) metastases at the basal level. The mPFS for this cohort was 19.7 months. Rashes (17.0%), skin decrustation (4.2%), pruritus (4.2%), dental ulcers (4.2%), increased creatine kinase (2.1%), and musculoskeletal pains (2.1%) were the most prevalent AEs in this study. Grade 3 and higher AEs were observed at a rate of 4.2%. <b>Conclusion:</b> This study concluded that aumolertinib has considerable safety and efficacy for <i>EGFR</i>-mutant NSCLC in a first-line defense.},
DOI = {10.32604/or.2025.064119}
}